Clinical Trials Logo

Refractory Multiple Myeloma clinical trials

View clinical trials related to Refractory Multiple Myeloma.

Filter by:

NCT ID: NCT03952091 Recruiting - Clinical trials for Refractory Multiple Myeloma

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: March 27, 2019
Phase: Phase 3
Study type: Interventional

A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received at least 1 prior line of treatment

NCT ID: NCT03860038 Recruiting - Clinical trials for Refractory Multiple Myeloma

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: January 28, 2019
Phase: Phase 2
Study type: Interventional

This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines of treatment.

NCT ID: NCT03731832 Recruiting - Clinical trials for Refractory Multiple Myeloma

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide: A Study in Relapsed or Refractory Multiple Myeloma

Start date: September 20, 2018
Phase: Phase 2
Study type: Interventional

The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in the study. After the first 6 patients will have finished the first treatment cycle of the induction phase the DMC will assess safety and tolerability of the treatment schedule and decide about the further continuation of the study.

NCT ID: NCT03702725 Not yet recruiting - Multiple Myeloma Clinical Trials

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

NCT ID: NCT03618602 Recruiting - Clinical trials for Refractory Multiple Myeloma

Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients

Start date: April 25, 2018
Phase: Phase 1
Study type: Interventional

This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Bisthianostat in refractory or recurrent multiple myeloma patients.

NCT ID: NCT03601624 Recruiting - Clinical trials for Refractory Multiple Myeloma

Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans

MM-POM-2018
Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

Despite available therapies, MM uniformly fatal and participants who have received prior lenalidomide (Len) and bortezomib have a median overall survival (OS) of 9 months. Pomalidomide (Pom) plus low-dose dexamethasone (Dex) significantly improved efficacy parameters in terms of progression free survival (PFS), OS, and overall response (ORR) compared with high-dose Dex in participants with refractory or relapsed, and refractory MM, including participants with disease refractory to both bortezomib and lenalidomide. Alkylating agents also represent standard therapies for participants with MM. There are some reports demonstrating combination of Len and continuous cyclophosphamide (Cy) achieve an ORR of 50% in Len refractory participants, suggesting Cy may be able to overcome resistance to Len. The investigators aimed to assess the safety in Mexican MM participants in relapse/refractory stage of the triple combination: IV Cy in combination with Pom plus Dex until disease progression. A multicenter study is proposed. Primary endpoint: Safety. Efficacy as secondary endpoint: PF, OS and ORR.

NCT ID: NCT03589222 Recruiting - Clinical trials for Refractory Multiple Myeloma

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Start date: July 15, 2018
Phase: Phase 2
Study type: Interventional

Phase 2, single-arm, open, non-randomized, multicenter study of the SINEā„¢ compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. 100 mg selinexor (on days 1, 8, 15 and 22), plus 40 mg dexamethasone (20 mg IV the day of daratumumab and selinexor and 20 mg oral administration the day after daratumumab and selinexor) both weekly as continuous therapy. Bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 once weekly on days 1, 8, 15 and 22 during the cycles 1 to cycle 8, and on day 1 and day 15 of each cycle thereafter as continuous therapy. Daratumumab will be given via intravenous at dose of 16 mg/Kg on days 1, 8, 15 and 22 (weekly) during the cycles 1 and 2, every two weeks (on days 1 and 15) during the cycles 3 to 6 and on day 1 of each cycle thereafter as continuous therapy. Patients may continue indefinitely and there is no maximum treatment duration

NCT ID: NCT03520985 Recruiting - Clinical trials for Refractory Multiple Myeloma

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

OptiPOM
Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

Pomalidomide is an approved treatment for refractory multiple myeloma. Toxicity of pomalidomide in the pivotal MM-003 trial, was considerable, with 60% of patients experiencing drug-related G3/4 toxicity. Neutropenia (48% vs 16%) and pneumonia (13% vs 8%) were significantly more common in the pomalidomide arm. This resulted in frequent dose interruptions (67%) and dose reductions (27%). This suggests that for the majority of patients the 4 mg daily dosing schedule is too toxic, and that strategies to deliver reduced dosing of pomalidomide are of high practical relevance. The aim of this trial therefore is to establish that alternate day dosing of pomalidomide (4 mg q2d, d1-28) is non-inferior to daily dosing (4 mg d1-21 q28) in terms of efficacy of the drug with potentially less side effects.

NCT ID: NCT03266692 Recruiting - Multiple Myeloma Clinical Trials

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

NCT ID: NCT03201250 Recruiting - Multiple Myeloma Clinical Trials

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Start date: February 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory Multiple Myeloma who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor, cabozantinib.